Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 334-340

  Lin, Eugene ^a,b   Tsai, Shih Jen ^c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b VITA GENOMICS INC   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Antidepressants; Genome wide gene expression profiling; Genome wide microarray analysis; Major depressive disorder; Transcriptional profiling

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; LONG UNTRANSLATED RNA; MICRORNA; SMALL UNTRANSLATED RNA;

CAPRIN1 GENE; CLEC4A GENE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DUSP1 GENE; FKBP5 GENE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IRF7 GENE; KRT23 GENE; MAJOR DEPRESSION; MLC1 GENE; NONHUMAN; PATHOGENESIS; PLSCR1 GENE; PROK2 GENE; REVIEW; TMEM176A GENE; ZBTB16 GENE; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; GENE EXPRESSION; METABOLISM; MICROARRAY ANALYSIS; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOMARKERS; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MICROARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84941183602     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.02.008     Document Type: Review

References (57)

1. Belzeaux R., Bergon A., Jeanjean V., Loriod B., Formisano-Tréziny C., Verrier L., et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2012, 2:e185.
2. Blaveri E., Kelly F., Mallei A., Harris K., Taylor A., Reid J., et al. Expression profiling of a genetic animal model of depression reveals novel molecular pathways underlying depressive-like behaviours. PLoS One 2010, 5:e12596.
3. Blondal T., Jensby Nielsen S., Baker A., Andreasen D., Mouritzen P., Wrang Teilum M., et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 2013, 59:S1-S6.
4. Breitenstein B., Scheuer S., Holsboer F. Are there meaningful biomarkers of treatment response for depression?. Drug Discov Today 2014, 19:539-561.
5. Clark S.L., Adkins D.E., Aberg K., Hettema J.M., McClay J.L., Souza R.P., et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol Med 2012, 42:1151-1162.
6. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010, 16:1328-1332.
7. Dwivedi Y. Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications. Dialogues Clin Neurosci 2014, 16:43-61.
8. Fass D.M., Schroeder F.A., Perlis R.H., Haggarty S.J. Epigenetic mechanisms in mood disorders: targeting neuroplasticity. Neuroscience 2014, 264:112-130.
9. Gaiteri C., Ding Y., French B., Tseng G.C., Sibille E. Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders. Genes Brain Behav 2014, 13:13-24.
10. Garbett K.A., Vereczkei A., Kálmán S., Brown J.A., Taylor W.D., Faludi G., et al. Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression. Biol Psychiatry 2015, 77:256-265.
11. Gatt J.M., Burton K.L., Williams L.M., Schofield P.R. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res 2015, 60:1-13.
12. Guilloux J.P., Douillard-Guilloux G., Kota R., Wang X., Gardier A.M., Martinowich K., et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2012, 17:1130-1142.
13. Guilloux J.P., Bassi S., Ding Y., Walsh C., Turecki G., Tseng G., et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology 2015, 40:701-710.
14. Guo L., Zhao Y., Yang S., Zhang H., Chen F. An integrated analysis of miRNA, lncRNA, and mRNA expression profiles. Biomed Res Int 2014, 2014:345605.
15. Hepgul N., Cattaneo A., Zunszain P.A., Pariante C.M. Depression pathogenesis and treatment: what can we learn from blood mRNA expression?. BMC Med 2013, 11:28.
16. Hwang J.P., Tsai S.J., Hong C.J., Yang C.H., Lirng J.F., Yang Y.M. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging 2006, 27:1834-1837.
17. Kim S.J., Zhang Z., Sarkar C., Tsai P.C., Lee Y.C., Dye L., et al. Palmitoyl protein thioesterase-1 deficiency impairs synaptic vesicle recycling at nerve terminals, contributing to neuropathology in humans and mice. J Clin Invest 2008, 118:3075-3086.
18. Kishi T., Kitajima T., Tsunoka T., Okumura T., Ikeda M., Okochi T., et al. Possible association of prokineticin 2 receptor gene (PROKR2) with mood disorders in the Japanese population. Neuromolecular Med 2009, 11:114-122.
19. Krishnadas R., Cavanagh J. Depression: an inflammatory illness?. J Neurol Neurosurg Psychiatry 2012, 83:495-502.
20. Labermaier C., Masana M., Müller M.B. Biomarkers predicting antidepressant treatment response: how can we advance the field?. Dis Markers 2013, 35:23-31.
21. Lin E. Novel drug therapies and diagnostics for personalized medicine and nanomedicine in genome science, nanoscience, and molecular engineering. Pharm Regul Aff Open Access 2012, 1:e116.
22. Lin E., Chen P.S. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008, 9:935-946.
23. Lin E., Hsu S.Y. A Bayesian approach to gene-gene and gene-environment interactions in chronic fatigue syndrome. Pharmacogenomics 2009, 10:35-42.
24. Lin E., Tsai S.J. Gene-gene interactions in a context of individual variability in antipsychotic drug pharmacogenomics. Curr Pharmacogenomics Person Med 2011, 9:323-331.
25. Lin E., Tsai S.J. Novel diagnostics R&D for public health and personalized medicine in Taiwan: current state, challenges and opportunities. Curr Pharmacogenomics Person Med 2012, 10:239-246.
26. Lin E., Hwang Y., Wang S.C., Gu Z.J., Chen E.Y. An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics 2006, 7:1017-1024.
27. Lin E., Hwang Y., Liang K.H., Chen E.Y. Pattern-recognition techniques with haplotype analysis in pharmacogenomics. Pharmacogenomics 2007, 8:75-83.
28. Lin E., Hong C.J., Hwang J.P., Liou Y.J., Yang C.H., Cheng D., et al. Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic tyrosine kinase receptor 2 genes in geriatric depression. Rejuvenation Res 2009, 12:387-393.
29. Liu Z., Li X., Sun N., Xu Y., Meng Y., Yang C., et al. Microarray profiling and co-expression network analysis of circulating lncRNAs and mRNAs associated with major depressive disorder. PLoS One 2014, 9:e93388.
30. Mamdani F., Berlim M.T., Beaulieu M.M., Labbe A., Merette C., Turecki G. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl Psychiatry 2011, 1:e13.
31. Maness P.F., Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci 2007, 10:19-26.
32. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
33. Mehta D., Menke A., Binder E.B. Gene expression studies in major depression. Curr Psychiatry Rep 2010, 12:135-144.
34. Menke A. Gene expression: biomarker of antidepressant therapy?. Int Rev Psychiatry 2013, 25:579-591.
35. Menke A., Binder E.B. Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin Neurosci 2014, 16:395-404.
36. Menke A., Arloth J., Pütz B., Weber P., Klengel T., Mehta D., et al. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 2012, 37:1455-1464.
37. Morag A., Pasmanik-Chor M., Oron-Karni V., Rehavi M., Stingl J.C., Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics 2011, 12:171-184.
38. Nagano T., Fraser P. No-nonsense functions for long noncoding RNAs. Cell 2011, 145:178-181.
39. Ng S.Y., Lin L., Soh B.S., Stanton L.W. Long noncoding RNAs in development and disease of the central nervous system. Trends Genet 2013, 29:461-468.
40. Novianti P.W., Roes K.C., Eijkemans M.J. Evaluation of gene expression classification studies: factors associated with classification performance. PLoS One 2014, 9:e96063.
41. Oved K., Morag A., Pasmanik-Chor M., Oron-Karni V., Shomron N., Rehavi M., et al. Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics 2012, 13:1129-1139.
42. Oved K., Morag A., Pasmanik-Chor M., Rehavi M., Shomron N., Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Transl Psychiatry 2013, 3:e313.
43. Patel A. Review: the role of inflammation in depression. Psychiatr Danub 2013, 25(Suppl. 2):S216-S223.
44. Rezola A., Pey J., Tobalina L., Rubio A., Beasley J.E., Planes F.J. Advances in network-based metabolic pathway analysis and gene expression data integration. Brief Bioinform 2014, [Mar 13. [Epub ahead of print]].
45. Seifuddin F., Pirooznia M., Judy J.T., Goes F.S., Potash J.B., Zandi P.P. Systematic review of genome-wide gene expression studies of bipolar disorder. BMC Psychiatry 2013, 13:213.
46. Sequeira A., Gwadry F.G., Ffrench-Mullen J.M., Canetti L., Gingras Y., Casero R.A., et al. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 2006, 63:35-48.
47. Sequeira A., Klempan T., Canetti L., Ffrench-Mullen J., Benkelfat C., Rouleau G.A., et al. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 2007, 12:640-655.
48. Serretti A., Kato M., Kennedy J.L. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2008, 8:90-100.
49. Spijker S., Van Zanten J.S., De Jong S., Penninx B.W., van Dyck R., Zitman F.G., et al. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry 2010, 68:179-186.
50. Sullivan P.F., Fan C., Perou C.M. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:261-268.
51. Szczepankiewicz A., Leszczyńska-Rodziewicz A., Pawlak J., Narozna B., Rajewska-Rager A., Wilkosc M., et al. FKBP5 polymorphism is associated with major depression but not with bipolar disorder. J Affect Disord 2014, 164:33-37.
52. Ulrich-Merzenich G., Kelber O., Koptina A., Freischmidt A., Heilmann J., Müller J., et al. Novel neurological and immunological targets for salicylate-based phytopharmaceuticals and for the anti-depressant imipramine. Phytomedicine 2012, 19:930-939.
53. Valkanova V., Ebmeier K.P., Allan C.L. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 2013, 150:736-744.
54. Verma R., Mukerji M., Grover D., B-Rao C., Das S.K., Kubendran S., et al. MLC1 gene is associated with schizophrenia and bipolar disorder in Southern India. Biol Psychiatry 2005, 58:16-22.
55. Watanabe R.M. Statistical issues in gene association studies. Methods Mol Biol 2011, 700:17-36.
56. Wheeler H.E., Dolan M.E. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 2012, 13:55-70.
57. Whyte A., Jessen T., Varney S., Carneiro A.M. Serotonin transporter and integrin beta 3 genes interact to modulate serotonin uptake in mouse brain. Neurochem Int 2014, 73:122-126.